Precigen Reports $74.1 Million Revenue and $35.8 Million Net Income

What happened

Precigen reported third-quarter 2026 revenue of $74.1 million and net income of $35.8 million, versus revenue of $2.9 million and a net loss a year earlier. PAPZIMEOS net revenue rose 37% sequentially to $72.9 million, and operating cash flow was positive at $11.9 million.

Confirmed

Global impact / market context

The results show a sharp year-over-year improvement in reported revenue and income, while positive operating cash flow means the business generated cash from its operations. If PAPZIMEOS sales continue growing, they could support revenue and cash generation; the supplied figures do not establish whether this pace will last.

Analyst inference

PAPZIMEOS accounted for $72.9 million of the $74.1 million in quarterly revenue, so the reported total was heavily concentrated in that product. More than 500 patients had started treatment, but the article provides no future sales guidance or evidence that adoption will continue at the same pace.

Analyst inference

What to watch

1. Watch whether PAPZIMEOS net revenue continues to grow in later quarters; its reported 37% sequential increase compares with the immediately preceding quarter. Analyst inference
2. Track whether Precigen keeps generating cash from its ordinary business activities and how its reported cash and investments change, since these figures indicate resources available to fund operations. Analyst inference
3. Follow developments around the FDA’s Platform Technology Designation for AdenoVerse; the article says it may support candidate development by allowing use of existing manufacturing and preclinical data. Proposed

Evidence

• Original source link unavailable